The short version of prohibited list fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
AlPhos allows for the mild Pd-catalyzed fluorination of aryl- and heteroaryl triflates. Reported in 2015, this ligand has been used for Buchwald-Hartwig cross-coupling reactions and synthesizing highly regioselective aryl fluorides through Pd-catalyzed fluorination of various activated aryl and heteroaryl triflates and bromides. Its palladium complexes have also been used to prepare aryl thioethers by C–S cross-coupling of thiols with aromatic electrophiles.
Other major football, ice hockey, and basketball teams are based in Moscow. Because sports organizations in the Soviet Union were once centralized, two of the best Union-level teams represented defense and law-enforcement agencies: the Armed Forces (CSKA) and the Ministry of Internal Affairs (Dinamo). Most major cities had army and police sports teams. As a result, Spartak, CSKA, and Dinamo were among the best-funded teams in the USSR. The Irina Viner-Usmanova Gymnastics Palace is located in the Luzhniki Olympic Complex. Construction of the Palace started in 2017, and the opening ceremony took place on 18 June 2019. The Palace was financed by billionaire Alisher Usmanov, husband of the former gymnast and gymnastics coach Irina Viner-Usmanova. The total area of the building is 23,500 square meters (253,000 sq ft), which includes three fitness rooms, locker rooms, rooms for referees and coaches, saunas, a canteen, a cafeteria, two ball halls, a medical center, a hall for journalists, and a hotel for athletes. Because of Moscow's cold climate, winter sports are popular. Many of Moscow's parks offer marked trails for skiing and frozen ponds for skating.
==== Fibrous astrocytes ==== The fibrous astrocytes are usually located within white matter, have relatively few organelles, and exhibit long unbranched cellular processes. This type often has astrocyte endfeet processes that physically connect the cells to the outside of capillary walls when they are in proximity to them.
The essential oil of frankincense is produced by steam distillation of the tree resin. The oil's chemical components are 75% monoterpenes, sesquiterpenes, and ketones. Contrary to some commercial claims, steam distilled frankincense oils do not contain the insufficiently volatile boswellic acids (triterpenoids), although they may be present in solvent extractions. The chemistry of the essential oil is mainly monoterpenes and sesquiterpenes, such as A-pinene, limonene, and B-pinene. The terpenic smell of frankincense oil is described as "terpenic, incense, peppery, spicy, old wood, woody, pine, resinous, green".
=== Activin === Activin A is more plentiful in the adipose tissue of obese, compared to lean persons. Activin A promotes the proliferation of adipocyte progenitor cells, while inhibiting their differentiation into adipocytes. Activin A also increases inflammatory cytokines in macrophages. A mutation in the gene for the activin receptor ACVR1 results in fibrodysplasia ossificans progressiva, a fatal disease that causes muscle and soft tissue to gradually be replaced by bone tissue. This condition is characterized by the formation of an extra skeleton that produces immobilization and eventually death by suffocation. The mutation in ACVR1 causes FKBP1A, which normally acts as an antagonist of the receptor and blocks osteogenesis (bone growth), to behave as an agonist of the receptor and to induce hyperactive bone growth. On 2 September 2015, Regeneron Pharmaceuticals announced that they had developed an antibody for activin A that effectively cures the disease in an animal model of the condition. Mutations in the ACVR1 gene have also been linked to cancer, especially diffuse intrinsic pontine glioma (DIPG). Elevated Activin B levels with normal Activin A levels provided a possible biomarker for myalgic encephalomyelitis/chronic fatigue syndrome. Activin A is overexpressed in many cancers. It was shown to promote tumorigenesis by hampering the adaptive anti-tumor immune response in melanoma.
Sources: en.wikipedia.org
This causes the inhibition of pro-inflammatory and pruritogenic (itch-causing) cytokines that depend on JAK1 and JAK3, which include IL-2, IL-4, IL-6, IL-13, and IL-31 (TSLP, another pruritogenic cytokine that uses JAKs, has also been found to be inhibited). IL-31 is a key cytokine at the pruritogenic receptors at neurons near the skin, and also induces peripheral blood mononuclear cells and keratinocytes to release pro-inflammatory cytokines. Suppression of IL-4 and IL-13 causes a decrease of Th2-cell differentiation, which plays a role in atopic dermatitis. Oclacitinib's relatively little effect on JAK2 prevent it from suppressing hematopoiesis or the innate immune response. Oclacitinib inhibits JAK, not the pruritogenic cytokines themselves; studies in mice showed that suddenly stopping the medication caused an increase in itchiness caused by a rebound effect, where more cytokines were produced to overcome lack of response by JAK.
The enzyme can also act on putrescine, which has one extra CH2 in the diamine component, to give carboxyspermidine. Vibrio cholerae uses this enzyme in combination with carboxynorspermidine decarboxylase to make spermidine and norspermidine. This sequence is the dominant pathway to spermidine used by gut microbiota in humans.
== Localization and export == MBP is exported into the periplasmic space of E. coli. The NH2-terminal extension of MBP, also termed signal peptide, has two roles: (i) it slows down folding of the newly synthesized polypeptide, and (ii) it directs this polypeptide to the membrane and SecYEG translocon. Once folded, the precursor can no longer enter the translocation pathway. The introduction of a charged amino-acid residue or a proline residue within the hydrophobic core of the signal peptide is sufficient to block export. The defective exports of the mutant MBPs are consistent with the alpha-helical conformation and hydrophobic interactions of the signal peptide in its interaction with the translocon motor protein SecA.
== Types == Neurotherapy, like many medical therapies, is based on knowledge from conventional medicine, relying on a scientific approach and evidence-based practice. However, some neuromodulation techniques are still attributed to alternative medicine (healthcare procedures "not readily integrated into the dominant healthcare model") because of their novelty and lack of evidence to support them. The wide range of neurotherapy techniques can be divided into three groups based on the application of energy stimulus:
== Further reading == Breker, Arno (1970). Patis, Hitler et moi. Paris: Presses de la Cité. Giesler, Hermann (1977). Ein anderer Hitler: Bericht seines Architekten: Erlebnisse, Gespräche, Reflexionen (2nd ed.). Leoni am Starnberger See: Druffel. ISBN 978-3-8061-0820-0. Larsson, Lars Olof (1998). Albert Speer: Plan de Berlin, 1937-1943. [S.I.]: Aam. ISBN 978-2-87143-034-6. O'Donnell, James (1978). The Bunker. New York: Da Capo Press. ISBN 978-0-306-80958-3. Scobie, Alexander (1990). Hitler's State Architecture: The Impact of Classical Antiquity. University Park: Pennsylvania State University Press. ISBN 978-0-271-00691-8. Speer, Albert (1996). Erinnerungen. Frankfurt am Main: Ullstein. ISBN 978-3-550-07616-9. Speer, Albert (1970). Inside The Third Reich. New York: Macmillan. ISBN 978-0-380-00071-5.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.